Proteinuria News and Research

RSS

Proteinuria, also sometimes referred to as albuminuria or urine albumin, is a health condition characterized by an abnormal concentration of protein in the urine.

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Avosentan shows prmoise for diabetic kidney disease

A new drug called avosentan significantly lowers urinary protein excretion-an important marker of kidney disease progression-in patients with diabetic kidney disease, according to an international clinical trial appearing in the March 2009 issue of the Journal of the American Society Nephrology (JASN).

16 Feb 2009

Candesartan cilexetil reduces proteinuria in kidney disease patients

Taking a much higher than recommended dose of the hypertension drug candesartan cilexetil effectively lowered the amount of protein excreted in the urine of patients with kidney disease, according to a study appearing in the April 2009 issue of the Journal of the American Society Nephrology ( JASN ).

11 Feb 2009

Protein in urine could be a predictor of heart disease

Scientists at the George Institute for International Health say urine tests should be incorporated into analysing heart disease risk.

29 Oct 2008

Genentech announces phase III study of Avastin plus chemotherapy in adjuvant colon cancer will continue

Genentech, Inc. today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned.

20 Oct 2008

New clues into how preeclampsia may surface in some pregnancies

The COMT gene - known already for its role in schizophrenia - has been found to play a role in preeclampsia, according to a report in the advance on-line issue of Nature.

11 May 2008

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines

The general public is not sufficiently aware that chronic kidney disease (CKD) is a serious and progressive medical condition.

1 Mar 2008

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Avastin approved in Europe for advanced lung cancer

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.

26 Aug 2007

Testosterone replacement therapy for men

For decades, older women have taken hormone replacements to replenish estrogen and progesterone levels lost to aging.

9 Aug 2007

Combination of blood pressure-lowering drugs stops loss of kidney function in rare genetic disease

A combination of two types of blood pressure-lowering drugs, an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, MA) is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.

26 Jul 2007

Aspirin during pregnancy could reduce risk of pre-eclampsia

Women who receive aspirin or other antiplatelet drugs during pregnancy are at lower risk of pre-eclampsia, conclude authors of an article published in an upcoming edition of The Lancet.

20 May 2007

ACE inhibitors help preserve kidney function in IgA nephropathy

For young patients with the kidney disease IgA nephropathy (IgAN), early treatment with angiotensin-converting enzyme (ACE) inhibitors can reduce the long-term risk of irreversible kidney damage, suggests a study in the June Journal of the American Society of Nephrology.

17 May 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

Study shows Diovan reduced urinary protein excretion in patients with type 2 diabetes and high blood pressure

In patients with high blood pressure and type 2 diabetes, the blood pressure-lowering medication Diovan (valsartan) significantly reduced urinary protein excretion, with high doses providing the greatest sustained reduction , according to data presented at the Amer ican Heart Association's (AHA) Annual Scientific Sessions.

13 Nov 2006

Discovery of protein associated with severe preeclampsia

Researchers have identified a second protein which, in combination with sFlt1, escalates preeclampsia to a severe - and life-threatening - state.

6 Jun 2006

Long-term clinical follow up of children with primary vesicoureteric reflux

It is documented that vesicoureteric reflux (VUR) is a predisposing factor for UTI, which in turn may involve the kidney parenchyma and cause permanent renal scarring.

6 Apr 2006

Antioxidant therapy will be useful for women with pre-eclampsia

The antioxidant tempol prevents the onset of pre-eclampsia in pregnant mice, a finding that further implicates oxidative stress in the illness, which is widespread among pregnant women.

4 Apr 2006

PR Pharmaceuticals issued U.S. patent covering 2-methoxyestradiol for the treatment of diabetes

The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).

21 Mar 2006